{
    "id": 4013,
    "name": "urethra transitional cell carcinoma",
    "source": "DOID",
    "definition": "An urethra cancer that is characterized by cancer cells forming in the renal pelvis and ureter. [url:http\\://cancer.emedtv.com/transitional-cell-carcinoma-%28of-the-ureter-and-renal-pelvis%29/transitional-cell-carcinoma-%28of-the-ureter-and-renal-pelvis%29.html]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4013",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00942331",
            "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1295,
                    "therapyName": "Bevacizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01108055",
            "title": "Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1143,
                    "therapyName": "Paclitaxel + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01174121",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01215136",
            "title": "First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01326871",
            "title": "A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2187,
                    "therapyName": "ALT-801",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01780545",
            "title": "Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1807,
                    "therapyName": "OGX-427",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014337",
            "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3053,
                    "therapyName": "Eribulin + Mifepristone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02091999",
            "title": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4125,
                    "therapyName": "Enfortumab vedotin-ejfv",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02108652",
            "title": "A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122172",
            "title": "Afatinib in Advanced Refractory Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02236195",
            "title": "Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3002,
                    "therapyName": "Mocetinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02240238",
            "title": "Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5626,
                    "therapyName": "Gemcitabine + NC-6004",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02256436",
            "title": "A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02300610",
            "title": "Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02302807",
            "title": "A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1685,
                    "therapyName": "Vinorelbine",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02334527",
            "title": "Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02335424",
            "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02365766",
            "title": "Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02365818",
            "title": "Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2523,
                    "therapyName": "CG0070",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02387996",
            "title": "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02401542",
            "title": "Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7035,
                    "therapyName": "Docetaxel + Vofatamab",
                    "synonyms": null
                },
                {
                    "id": 2934,
                    "therapyName": "Vofatamab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02426125",
            "title": "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02437370",
            "title": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02459119",
            "title": "Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02479178",
            "title": "A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3640,
                    "therapyName": "BIND-014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02496208",
            "title": "Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2067,
                    "therapyName": "Cabozantinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02500121",
            "title": "Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02516241",
            "title": "Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 4686,
                    "therapyName": "Carboplatin + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02553642",
            "title": "Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559492",
            "title": "INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3096,
                    "therapyName": "Epacadostat + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02567409",
            "title": "Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 3110,
                    "therapyName": "Cisplatin + Gemcitabine + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02581982",
            "title": "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02589717",
            "title": "An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy",
            "phase": "FDA approved",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02612194",
            "title": "LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02619253",
            "title": "Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3077,
                    "therapyName": "Pembrolizumab + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02788201",
            "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 2563,
                    "therapyName": "Thiotepa",
                    "synonyms": null
                },
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                },
                {
                    "id": 1154,
                    "therapyName": "Dacarbazine",
                    "synonyms": null
                },
                {
                    "id": 640,
                    "therapyName": "Arsenic trioxide",
                    "synonyms": null
                },
                {
                    "id": 1022,
                    "therapyName": "Idarubicin",
                    "synonyms": null
                },
                {
                    "id": 1133,
                    "therapyName": "Mitomycin C",
                    "synonyms": null
                },
                {
                    "id": 1641,
                    "therapyName": "Thioguanine",
                    "synonyms": null
                },
                {
                    "id": 1640,
                    "therapyName": "Mercaptopurine",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 1767,
                    "therapyName": "Cladribine",
                    "synonyms": null
                },
                {
                    "id": 1013,
                    "therapyName": "Epirubicin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 1137,
                    "therapyName": "Bleomycin",
                    "synonyms": null
                },
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 751,
                    "therapyName": "Gefitinib",
                    "synonyms": null
                },
                {
                    "id": 1006,
                    "therapyName": "Daunorubicin",
                    "synonyms": null
                },
                {
                    "id": 2075,
                    "therapyName": "Lomustine",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1441,
                    "therapyName": "Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 2206,
                    "therapyName": "Asparaginase",
                    "synonyms": null
                },
                {
                    "id": 781,
                    "therapyName": "Ixabepilone",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                },
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                },
                {
                    "id": 2950,
                    "therapyName": "Estramustine",
                    "synonyms": null
                },
                {
                    "id": 1941,
                    "therapyName": "Floxuridine",
                    "synonyms": null
                },
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                },
                {
                    "id": 1811,
                    "therapyName": "Carmustine",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 953,
                    "therapyName": "Vandetanib",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 4419,
                    "therapyName": "Toremifene",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 2601,
                    "therapyName": "Dactinomycin",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                },
                {
                    "id": 3035,
                    "therapyName": "Chlorambucil",
                    "synonyms": null
                },
                {
                    "id": 3161,
                    "therapyName": "Pentostatin",
                    "synonyms": null
                },
                {
                    "id": 728,
                    "therapyName": "Eribulin",
                    "synonyms": null
                },
                {
                    "id": 1624,
                    "therapyName": "Carfilzomib",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1750,
                    "therapyName": "Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 738,
                    "therapyName": "Exemestane",
                    "synonyms": null
                },
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1740,
                    "therapyName": "Mitoxantrone",
                    "synonyms": null
                },
                {
                    "id": 2635,
                    "therapyName": "Vinblastine",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 1746,
                    "therapyName": "Clofarabine",
                    "synonyms": null
                },
                {
                    "id": 4305,
                    "therapyName": "Teniposide",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1104,
                    "therapyName": "Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 4304,
                    "therapyName": "Streptozocin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                },
                {
                    "id": 4303,
                    "therapyName": "Mechlorethamine",
                    "synonyms": null
                },
                {
                    "id": 4302,
                    "therapyName": "Mitotane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02807636",
            "title": "The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4450,
                    "therapyName": "Atezolizumab + Carboplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02812420",
            "title": "Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02853305",
            "title": "Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 4686,
                    "therapyName": "Carboplatin + Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02897765",
            "title": "A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4733,
                    "therapyName": "NEO-PV-01 + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02925533",
            "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4831,
                    "therapyName": "Pembrolizumab + Vofatamab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02989064",
            "title": "MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02989584",
            "title": "A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5140,
                    "therapyName": "Atezolizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03093922",
            "title": "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5140,
                    "therapyName": "Atezolizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132922",
            "title": "MAGE-A4c1032T for Multi-Tumor",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7280,
                    "therapyName": "ADP-A2M4 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03170960",
            "title": "Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6094,
                    "therapyName": "Atezolizumab + Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03237780",
            "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 6098,
                    "therapyName": "Atezolizumab + Eribulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03272217",
            "title": "Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03317496",
            "title": "Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6515,
                    "therapyName": "Avelumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 6514,
                    "therapyName": "Avelumab + Carboplatin + Pemetrexed",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03359239",
            "title": "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6556,
                    "therapyName": "Atezolizumab + PGV 001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361865",
            "title": "Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03374488",
            "title": "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03397394",
            "title": "Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 906,
                    "therapyName": "Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03410693",
            "title": "Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2030,
                    "therapyName": "Rogaratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03451331",
            "title": "Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7292,
                    "therapyName": "Carboplatin + Gemcitabine + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7293,
                    "therapyName": "Gemcitabine + Nivolumab + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03459846",
            "title": "A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03473756",
            "title": "Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 6822,
                    "therapyName": "Atezolizumab + Rogaratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03502785",
            "title": "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7129,
                    "therapyName": "Atezolizumab + INO-5401 + INO-9012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03513952",
            "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6915,
                    "therapyName": "Atezolizumab + CYT107",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517956",
            "title": "Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7106,
                    "therapyName": "Copanlisib + Rogaratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03557918",
            "title": "Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03575013",
            "title": "A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7116,
                    "therapyName": "Avelumab + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628716",
            "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7332,
                    "therapyName": "Atezolizumab + CV301",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03666988",
            "title": "First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9261,
                    "therapyName": "GSK3368715",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03682068",
            "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7523,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 7524,
                    "therapyName": "Carboplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 7461,
                    "therapyName": "Cisplatin + Durvalumab + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 7525,
                    "therapyName": "Cisplatin + Durvalumab + Gemcitabine + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 2667,
                    "therapyName": "Carboplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03737123",
            "title": "Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4450,
                    "therapyName": "Atezolizumab + Carboplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03821935",
            "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7795,
                    "therapyName": "ABBV-151",
                    "synonyms": null
                },
                {
                    "id": 7796,
                    "therapyName": "ABBV-151 + ABBV-181",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03869190",
            "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS mUC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8042,
                    "therapyName": "Atezolizumab + Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 8040,
                    "therapyName": "Atezolizumab + Niraparib",
                    "synonyms": null
                },
                {
                    "id": 8041,
                    "therapyName": "Atezolizumab + Hu5F9-G4",
                    "synonyms": null
                },
                {
                    "id": 8039,
                    "therapyName": "Atezolizumab + Enfortumab vedotin-ejfv",
                    "synonyms": null
                },
                {
                    "id": 6276,
                    "therapyName": "Atezolizumab + Linagliptin",
                    "synonyms": null
                },
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03898180",
            "title": "Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03915405",
            "title": "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8674,
                    "therapyName": "Avelumab + KHK2455",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03935347",
            "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 8500,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03980041",
            "title": "Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8645,
                    "therapyName": "IPI-549 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04004442",
            "title": "Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (COAXIN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9457,
                    "therapyName": "AVB-S6-500 + Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04143711",
            "title": "Study of DF1001 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8896,
                    "therapyName": "DF1001",
                    "synonyms": null
                },
                {
                    "id": 8897,
                    "therapyName": "DF1001 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}